...

Lundbeck

Visit website

About the employer

About Lundbeck

Lundbeck is a global pharmaceutical company highly committed to improving the quality of life of people living with psychiatric and neurological disorders. For this purpose, Lundbeck is engaged in the research, development, production, marketing and sale of pharmaceuticals across the world. The company’s products are targeted at disease areas such as depression, schizophrenia, Parkinson’s disease and Alzheimer’s disease.

More information about Lundbeck

Psychiatric and neurological disorders
According to the World Health Organization, WHO, more than 700 million people lives with psychiatric and neurological disorders globally. These are serious and life-threatening diseases that affect the quality of life of the patients as well as of their relatives.

As these diseases also involve major socio-economic costs, it is imperative for the general society that new and innovative pharmaceuticals are developed. Over the past 50 years, new pharmaceuticals have revolutionised the treatment options, but there remains a large unmet need for new and innovative therapeutics.

More information about disease areas

Research and development
Focus on R&D is the most important pillar in Lundbeck’s ambition to improve treatment for people living with psychiatric and neurological disorders. We are specialists in our area and have research facilities in Denmark and China, and more than 1,000 employees work in our R&D units. We cooperate closely with strategic partners all over the world, ensuring the best possible foundation for innovation and the development of new treatment solutions.

More information about developing drugs

Products
Lundbeck markets a number of different pharmaceuticals for the treatment of psychiatric and neurological disorders. The most recently launched compounds include: Rexulti® (depression and schizophrenia), Brintellix® (depression) and Abilify Maintena® (schizophrenia).

More information about products

Key figures
Lundbeck employs approximately 5,000 people worldwide. We have employees in 55 countries, and our products are registered in more than 100 countries. We have production facilities in Denmark, France and Italy and research centres in Denmark and China. Lundbeck generated revenue of approximately DKK 15.6 billion in 2016.

More key figures

History
Lundbeck was founded by Hans Lundbeck as a trading company in 1915. Since then the company has evolved and grown dramatically. Today we are among the biggest Danish companies. During the past century, millions of people have been treated with our therapies. It is complex and challenging to develop improved treatments for psychiatric and neurological disorders, but we keep our focus in order to ensure a better life for people living with psychiatric and neurological disorders.

More information about our history

The Lundbeck Foundation

The Lundbeck Foundation is the largest shareholder of Lundbeck, owning 70% of the company. It is an active industrial foundation established in 1954 by Grete Lundbeck, widow of the founder of Lundbeck.

The objective of the Foundation is in part to maintain and expand the activities of Lundbeck as well as of the Foundation’s other subsidiaries and portfolio companies through active value-adding ownership, and in part to provide grants for scientific research of the highest international quality in order to make a significant difference to human health and life. Grants are given based on external peer review and independently of Lundbeck.

In addition to its ownership of Lundbeck, the Foundation also has controlling shareholdings in ALK and Falck and manages its portfolio of financial investments through Lundbeckfond Invest and Lundbeckfond Ventures. The Foundation annually grants between DKK 400-500 million to support medical research and educational and communication activities.

The Lundbeck Foundation has in recent years increased its focus on personal grants. The Foundation’s latest initiative, Lundbeckfond Emerge, works to accelerate the commercialization of early scientific projects by way of investment and active project participation.

For further information about the Foundation, please visit www.lundbeckfonden.com.

The Lundbeck Institute

The mission of The Lundbeck Institute is to develop, provide and cascade unbiased, evidence-based medical education in psychiatry and neurology from leading experts to health care professionals and create a forum to facilitate knowledge sharing, networking and collaborations.

Psychiatric and neurological disorders are prevalent and impose an enormous burden, not only for patients and their families but also for broader society. The impact of these diseases is underestimated, and their management generally under-resourced.

Our aim is to provide accessible high quality medical education worldwide, to support health care professionals improve quality of life of people living with psychiatric or neurological disorders through up-to-date disease understanding leading to optimized care.

Strong legacy, stronger future
Since its foundation in 1997, The Lundbeck Institute has been committed to providing expert, international, interactive seminars, thereby building a valued legacy in medical education. The seminars cover mood disorders, schizophrenia, dementia and Parkinson’s disease*. In addition we offer educational materials, and tools for facilitating locally-run workshops.

Governance
The Lundbeck Institute's activities are governed and endorsed by the Lundbeck International Neuroscience Foundation (LINF) http://linf-forum.com/.

LINFs Faculty, composed of respected experts within psychiatry and neurology and other specialties throughout the world, is the basis of quality and objectivity. Faculty members provide scientific and clinical advice, moderate seminars, support local The Lundbeck Institute activities and endorse material available on the Lundbeck Institute Campus website. The editorial board of the Lundbeck Institute Campus website comprises LINF Faculty members.


*The Lundbeck Institute seminars, which cover mood disorders, schizophrenia, dementia and Parkinson’s disease, are open to all. Please note that The Lundbeck Institute cannot guarantee that there are places available at your chosen seminar. For further information on seminar content and seminar fees please contact us at seminars@lundbeck.com.

Discover related jobs

Discover similar employers

...
Aalborg University (AAU) Aalborg, Denmark 2 open positions
...
University of Southern Denmark Odense, Denmark 1 open positions
...
SFI - The Danish National Centre for Social Research Copenhagen, Denmark 0 open positions
...
IT University of Copenhagen (ITU) Copenhagen, Denmark 0 open positions
...
Design School Kolding Kolding, Denmark 0 open positions
More employers